Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: Lessons from the right and LEPHT

Circulation

Volumn 128, Issue 5, 2013, Pages 475-476

  Rubin, Lewis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; RIOCIGUAT; VASODILATOR AGENT;

ARTERIAL OXYGEN SATURATION; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HEART INDEX; HEART LEFT VENTRICLE FAILURE; HEART STROKE VOLUME; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LUNG ARTERY PRESSURE; LUNG CIRCULATION; OXYGEN SUPPLY; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; SIGNAL TRANSDUCTION; SURVIVAL RATE; SYMPTOM; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VASODILATATION;

EDITORIALS; HYPERTENSION, PULMONARY;

FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; PYRAZOLES; PYRIMIDINES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84881107484     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.004194     Document Type: Editorial

References (10)

1. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Tapson VF, Clayton LM, Crow JW; PPH Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-301.
2. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE, Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134:44-54.
3. Ghofrani HA, Galiè N, Grimminger F, Humbert M, Keogh AM, Langleben D, Kilama MO, Neuser D, Rubin LJ. Riociguat for the treatment of pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled study (PATENT-1). Chest. 2012;142:1027A.
4. Ghofrani HA, Grimminger F, Hoeper MM, Kim NH, Mayer E, Neuser D, Pena J, Simonneau G, Wilkins M. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: A randomized, double-blind, placebo-controlled study (CHEST-1). Chest. 2012;142:1023A.
5. Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, Oudiz RJ, Boateng F, Scalise AV, Roessig L, Semigran MJ; Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT) Study Group. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: A phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128:502-511.
6. Rubin LJ. Therapy of pulmonary hypertension: The evolution from vasodilators to antiproliferative agents [editorial]. Am J Resp Crit Care Med. 2002:166:1308-1309.
7. Hoeper M, Meyer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation. 2006;113:2011-2020.
8. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomised controlled trial. Lancet. 2002;360:895-900.
9. Provencher S, Hervé P, Sitbon O, Humbert M, Simonneau G, Chemla D. Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. Eur Respir J. 2008; 32:393-398.
10. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34:1219-1263.